Greehey CCRI News & Events Archive
Scientific Reports: Genomic analyses of early responses to radiation in glioblastoma reveal new alterations at transcription, splicing, and translation levels
January 1, 2020Choudhary Saket, Suzanne C Burns, Mirsafian Hoda, Wenzheng Li, Dat T Vo, Qiao Mei, Lei Xiufen, Andrew D Smith, Luiz O Penalva High-dose radiation is the main component of glioblastoma therapy. Unfortunately, radio-resistance is a common problem and a m …
bioRxiv: Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches
January 1, 2020Sajina Shakya, Anthony D Gromovsky, James S Hale, Arnon M Knudsen, Briana Prager, Lisa C Wallace, Luiz OF Penalva, Pavlina Ivanova, H Alex Brown, Bjarne W Kristensen, Jeremy N Rich, Justin D Lathia, J Mark Brown, Christopher G Hubert Background: Gliobl …
BMG Genomics: An ancestry informative marker panel design for individual ancestry estimation of Hispanic population using whole exome sequencing data
December 30, 2019Li-Ju Wang, Catherine W. Zhang, Sophia C. Su, Hung-I H. Chen, Yu-Chiao Chiu, Zhao Lai, Hakim Bouamar, Amelie G. Ramirez, Francisco G. Cigarroa, Lu-Zhe Sun & Yidong Chen Abstract Background Europeans and American Indians were the major genetic ances …
Molecular Carcinogenesis: PELP1 signaling contributes to medulloblastoma progression by regulating the NF‐κB pathway
December 24, 2019Yiliao Luo Mengxing Li Uday P. Pratap Suryavathi Viswanadhapalli Junhao Liu Prabhakar P. Venkata Kristin A. Altwegg Bridgitte E. Palacios Xiaonan Li Yihong Chen Manjeet K. Rao Andrew J. Brenner Gangadhara R. Sareddy Ratna K. Vadlamud Abstract Medullobl …
NATURE: Bishop lab helps discovery of R-loops in the pediatric cancer Embryonal tumors with multilayered rosettes (ETMRs)
December 18, 2019Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
December 17, 2019The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both …
Briefings in Bioinformatics: Deep learning of pharmacogenomics resources: moving towards precision oncology
December 8, 2019Yu-Chiao Chiu, Hung-I Harry Chen, Aparna Gorthi, Milad Mostavi, Siyuan Zheng, Yufei Huang, Yidong Chen Abstract The recent accumulation of cancer genomic data provides an opportunity to understand how a tumor’s genomic characteristics can affect its re …
Pediatric Blood & Cancer: Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children’s Oncology Group Phase 1 Consortium study (ADVL1411)
November 14, 2019Abstract Purpose We conducted a phase 1/2 trial of the poly(ADP‐ribose) polymerase 1/2 inhibitor talazoparib in combination with low‐dose temozolomide (TMZ) to determine the dose‐limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmaco …
Aging Cell: mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging
November 6, 2019Candice E. Van Skike, Ai‐Ling Lin, Raquel Roberts Burbank, Jonathan J. Halloran, Stephen F. Hernandez, James Cuvillier, Vanessa Y. Soto, Stacy A. Hussong, Jordan B. Jahrling, Martin A. Javors, Matthew J. Hart, Kathleen E. Fischer, Steven N. Austad, Ver …
Cell Reports: Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
November 5, 2019Author links open overlay panelJo LynneRokita123 Komal S.Rathi23 Maria F.Cardenas4 Kristen A.Upton1 JoyJayaseelan4 Katherine L.Cross5 JacobPfeil6 Laura E.Egolf17 Gregory P.Way8 AlvinFarrel2 Nathan M.Kendsersky19 KhushbuPatel2 Krutika S.Gaon …